Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Current Leases (2019 - 2026)

C4 Therapeutics has reported Current Leases over the past 8 years, most recently at $6.5 million for Q1 2026.

  • For Q1 2026, Current Leases rose 10.19% year-over-year to $6.5 million; the TTM value through Mar 2026 reached $6.5 million, up 10.19%, while the annual FY2025 figure was $6.4 million, 10.27% up from the prior year.
  • Current Leases for Q1 2026 was $6.5 million at C4 Therapeutics, up from $6.4 million in the prior quarter.
  • Over five years, Current Leases peaked at $6.5 million in Q1 2026 and troughed at $1.7 million in Q1 2022.
  • A 5-year average of $5.1 million and a median of $5.4 million in 2024 define the central range for Current Leases.
  • Biggest five-year swings in Current Leases: soared 288.87% in 2022 and later increased 10.19% in 2026.
  • Year by year, Current Leases stood at $4.7 million in 2022, then grew by 11.04% to $5.2 million in 2023, then grew by 10.63% to $5.8 million in 2024, then rose by 10.27% to $6.4 million in 2025, then grew by 2.43% to $6.5 million in 2026.
  • Business Quant data shows Current Leases for CCCC at $6.5 million in Q1 2026, $6.4 million in Q4 2025, and $6.2 million in Q3 2025.